Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
Poulter
N R
NR
Chang
C L
CL
Farley
T M
TM
Meirik
O
O
D000328:Adult; D016022:Case-Control Studies; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced; D016017:Odds Ratio; D045167:Progesterone Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced*; D014944:World Health Organization
D003280:Contraceptives, Oral, Synthetic; D045167:Progesterone Congeners